Skip to main content

Author: Johnny Green

Will Pennsylvania’s Cannabis Laws Become ‘The Gold Standard’?

An increasing number of states have legalized cannabis for adult use, with even more states exploring the idea of passing an adult-use legalization law either via citizen initiative or through the legislative process.

One of those states is Pennsylvania, which has operated in an exploratory phase for a while now when it comes to cannabis legalization. 

Ten states plus the District of Columbia have already implemented some form of adult-use legalization, and Illinois is set to enact its own adult-use legalization law at the beginning of the new year.

Legalization models vary by jurisdiction, with no two models being exactly alike. It’s debatable as to which jurisdiction currently has the best law.

A bill in Pennsylvania, if passed, would make that state the most progressive in the nation when it comes to cannabis policy. Some of the provisions of the bill include:

  • Home cultivation
  • Automatic expungements for qualifying citizens
  • Social cannabis use
  • Equity-focused cannabis business loans
  • Legal cannabis delivery services

For those that may be skeptical as to if the bill, which was introduced by State Sens. Sharif Street (D., Phila.) and Daylin Leach (D., Montgomery), is as progressive as some cannabis advocates are claiming, look no further than one of the top cannabis minds in the nation. Per The Philadelphia Inquirer:

“Wow, this is impressive,” said Shaleen Title, of the Massachusetts Cannabis Control Commission. “It’s largely in line with the trend that each state’s legalization law improves upon the states before it.”

Shaleen Title wrote the legalization law that was passed by Massachusetts voters in 2016. Massachusetts is considered by many cannabis advocates to have the best all-around cannabis legalization law in the country right now.

Receiving praise from Shaleen for cannabis legislation is something that curious minds can take to the bank. If she is impressed by the legislation, it’s safe to say that it is solid.

However, just because a bill is thought out and well-written does not necessarily mean that its passage is guaranteed.

The legislation will have to work its way through both chambers of Pennsylvania’s legislature and be signed by the Governor before it can be implemented. Pennsylvania’s Governor recently announced support for adult-use cannabis legalization.

Pennsylvania appears to be moving towards legalization. Only time will tell if this particular reform measure is the one that makes it all the way to the political finish line.

Canada’s Arthritis Society: Sell Medical Cannabis In Pharmacies

Cannabis is medicine. That may seem like a simple statement, yet despite an ever-growing mountain of evidence to support the claim, cannabis is often not treated as actual medicine. Many states in the U.S. and countries around the world continue to view cannabis as possessing no medical value.

Most professional sports leagues do not recognize the medical benefits of cannabis. Even in places where cannabis is legal for medical use and/or adult-use, cannabis is often not treated the same way as other medicines. Why is that?

Canada’s Arthritis Society came out recently calling for cannabis to be treated like other medicines, including a call for Canadian pharmacies to sell medical cannabis. Per CBC:

Canada’s Arthritis Society is taking advantage of the federal election to lobby the federal parties to change some of the ways medical marijuana is handled.

They’re asking the parties to commit to lift the $1 a gram federal excise tax, and have medical cannabis dispensed only at pharmacies.

“Just like other prescription medications,” said Jone Mitchell, the society’s executive director for Atlantic Canada.

“That will ensure that patients receive reliable education from trained health care professionals on the safe and effective use. And they also have an understanding of the other medications their patients may be taking.”

It would be convenient for patients to be able to purchase cannabis through pharmacies. Germany’s medical cannabis model is built on sales at pharmacies. For many patients, making their purchases at pharmacies would be ideal.

However, pharmacies should not be given the monopoly when it comes to medical cannabis sales. Not every patient can get to a pharmacy, which is why pharmacies should be one of the safe access options for patients, but not the only one. For some patients, other options are better for their particular situation.

One out of every five people over the age of 15 in Canada suffers from arthritis. Studies have found that cannabis can be an effective treatment for arthritis.

Jamaica’s Trade Minister: U.S. Cannabis Banking Reform Is Desperately Needed

Jamaica has a long history when it comes to cannabis. The cannabis plant is ingrained in the island nation’s culture, and thanks to cannabis reform efforts, it’s preparing to take its rightful place as an international cannabis industry leader.

The Carribean country is working to finalize rules and regulations for cannabis exports, with its sights set on lucrative international markets such as Germany and Australia. Jamaica’s Trade Minister Audley Shaw stated this week that there’s a major roadblock in the way right now – cannabis prohibition in the United States, and more specifically, banking issues related to the U.S. prohibition policy. Per Bloomberg:

“It’s really a roadblock, no other word for it, it’s a major roadblock in the advancement of medicinal cannabis,” Shaw said in an interview at Bloomberg’s New York office Wednesday.

He’s particularly passionate about marijuana’s potential to reduce opioid addiction rates, and is hoping to bring his message all the way to President Donald Trump.

“The gravity of this situation requires the highest level of focus,” he said.

Minister Shaw went on to point out the blatant hypocrisy of the United States allowing Canadian cannabis companies to list on its stock exchanges yet at the same time prohibiting United States cannabis companies from being able to do the same thing.

Shaw also pointed out that it’s ridiculous that there are serious hurdles for cannabis banking in his country due to U.S. policy while at the same time Canadian cannabis companies are able to offer stock options in the U.S.

Jamaica is not the only country experiencing banking issues due to the current United States cannabis policy. Uruguay has also reportedly experienced issues. The SAFE Banking Act was already approved by the United States House of Representatives. Hopefully the legislation passes soon in the U.S. Senate and is signed into law for the sake of the emerging cannabis industry in the U.S., Jamaica, and elsewhere.

Canadian Cannabis Company Aims To Undercut Unregulated Market Prices

One of the biggest benefits of legalizing and regulating cannabis sales is taking revenue away from the unregulated cannabis market. An unregulated cannabis market is never entirely operated by gangs and cartels, however, it is well documented that gangs and cartels do use illegal cannabis sales in some cases to help generate revenue.

Rather than having consumer dollars supporting those types of entities, it is much better for consumer dollars to support a regulated system in which revenue is generated by licensed entrepreneurs, some of which goes to taxes that support society. It is better for local economies and it is ultimately better for consumers who are able to purchase tested products that have met industry safety standards.

Convincing consumers to make their purchases through a regulated system is easier said than done. A number of factors affect consumer purchasing practices, with arguably the biggest factor being the cost of the cannabis to the end consumer.

Regulated options provide a number of non-monetary benefits including variety and convenience. However, those benefits only go so far. If regulated cannabis is significantly more expensive than unregulated cannabis, consumers will often make their purchases through unregulated sources.

A Canadian cannabis company has announced that it is going to offer a cannabis flower option that will cost less than the average price of cannabis flower from unregulated cannabis dispensaries. Per Global News:

Cannabis company Hexo Corp. says it is aiming to undercut prices in the illicit market with its new 28-gram product, that costs as much as one dollar less per gram than at a illegal dispensary.

Hexo says the product will be on sale in Quebec cannabis stores for $125.70 taxes included, or $4.49 per gram.

Statistics Canada’s latest price analysis based on crowdsourced data showed that the average cost of a gram of cannabis was $7.37 during the third quarter, with the price of legal and illegal weed slipping to $10.23 and $5.59 per gram, respectively.

The cannabis flower will be sold under the name ‘Original Stash’ and will have a THC content between the range of 12% and 18%. The THC percentage could be an issue and affect the potential success of the new offering. Many cannabis consumers prefer cannabis flower that tests at 20% or above.

The proposed price for the 28 grams of Original Stash could also be an issue too. $4.49 per gram may be lower than the average price of a gram at an unregulated dispensary in Canada, but it’s likely not lower than a non-dispensary gram of flower. Consumers may still be able to find cannabis for cheaper from a local dealer and continue to opt to make purchases from them.

With that being said, the lower price should still cut into unregulated cannabis sales to some extent. How much of an impact it will ultimately have is something that will be determined in the coming months as sales data is compiled and analyzed.

Zimbabwe Makes History With Planting Of First Legal Hemp Crop

Zimbabwe may not be the first place that people think of when they think of hemp, however, the African nation made history this month when it planted its first crop of hemp. Zimbabwe legalized the production of hemp last year for medical and scientific purposes and legalized hemp for industrial purposes in September of this year.

The Zimbabwe Industrial Hemp Trust (ZIHT) planted six different varieties of hemp. ZIHT was the first entity to receive a hemp cultivation license in Zimbabwe’s history. The license is valid for 5 years. It was a monumental development for Zimbabwe, as Zimbabwe’s Agricultural Minister pointed out according to Yahoo News:

“This project is the first of its kind in the history of our country,” Agriculture Minister Perence Shiri told guests at the launch in Harare central prison.

“This pilot project will provide essential knowledge or information for the successful production of this crop. The benefits that will be derived from the production of industrial hemp are enormous and varied,” he said.

The location of the historic hemp garden is significant in multiple ways. The fact that it used to be a prison is representative of both hemp prohibition’s past in Zimbabwe as well as how much times are changing on the African continent and around the world.

ZIHT has stated that it chose the site because security features were already built into the property, which makes sense. It’s not the first former correctional facility to be converted into a cannabis cultivation facility. Similar types of facilities in North America have been converted over the years.

However, this is the first time that the conversion of a prison facility has been doubled with it also simultaneously being the location of the first legal planting in a nation’s history, and that’s definitely worth celebrating.

What Is Canadian Cannabis Legalization 2.0?

Roughly a year ago Canada became the first G-7 nation to legalize cannabis for adult-use. Canada rolled out a regulated adult-use cannabis industry in a limited fashion last October. Canada’s model was built around cannabis flower sales, which will be changing soon.

In just a handful of weeks cannabis edibles, vape products, beverages, and other items will hit regulated cannabis store shelves in Canada. The delayed implementation is a result of Canadian lawmakers and regulators needing more time to come up with regulations for cannabis beyond just flower sales.

By mid-December, the new products will go on sale in Canada which is going to be a really big milestone for Canada’s cannabis industry. The historic launch is being dubbed ‘cannabis 2.0’ in media coverage around the globe. Cannabis 2.0 is expected to provide a significant boost to Canada’s economy. Per Financial Post:

The introduction of extracts is estimated to add an additional $2.7 billion to the cannabis market, according to Deloitte, but as producers add dozens of new products, retailers may already be facing a crunch in terms of how much of it they can actually carry.

Cannabis 2.0 will help address the ongoing issue of consumers continuing to purchase cannabis products from Canada’s unregulated market. Consumers want more options than just cannabis flower. The unregulated industry will never be eliminated in Canada, however, many consumers prefer to purchase cannabis from regulated sources as long as the prices are reasonable. Hopefully that proves to be the case in Canada.

Price points and shelf access are going to be two really big determining factors as to whether cannabis 2.0 is successful or misses the mark. If cannabis edibles and other new products are expensive and hard to find, it will obviously result in consumers continuing to turn to unregulated sources.

Australian Government Wants To See Evidence That Cannabis Legalization Works

Last month the Australian Capital Territory (ACT) became the first jurisdiction in Australia to legalize cannabis for adult use. The ACT measure allows adults 18 years old or older within its jurisdiction to possess up to 50 grams of cannabis and cultivate up to two plants. The measure did not legalize cannabis sales.

It did not take long for Australia’s federal government to take issue with the measure’s passage, despite the measure not taking effect immediately. The measure was coupled with increases in substance addiction services in the ACT, yet despite that, Australia’s federal government is coming out strong against the measure citing societal ‘health concerns.’ Per ABC News:

Federal Health Minister Greg Hunt has penned a letter to ACT Chief Minister Andrew Barr, calling on him to produce any evidence he considered before supporting the legislation, regarding the health impacts of cannabis.

“I call on you to explain whether the ACT Government considered the international evidence on the health effects of cannabis and to provide any evidence to the contrary,” he wrote.

Cannabis has been found by a number of studies and personal patient experiences to possess tremendous wellness benefits. The cannabis plant can be used to treat a number of conditions. Below are examples of studies that have found that cannabis use is associated with better brain health:

  • “Marijuana use is estimated to reduce premature deaths from diabetes mellitus, cancer, and traumatic brain injury by 989 to 2,511 deaths for each 1% of the population using Cannabis. The analysis predicts an estimated 23,500 to 47,500 deaths prevented annually if medical marijuana were legal nationwide.” - Indiana University South Bend (2017)
  • “Results suggest that an ultralow dose of THC that lacks any psychotrophic activity protects the brain from neuroinflammation-induced cognitive damage and might be used as an effective drug for the treatment of neuroinflammatory conditions, including neurodegenerative diseases” - Fishbein-Kaminietsky, M., Gafni, M. and Sarne, Y. (2014)
  • “A positive THC screen is associated with decreased mortality in adult patients sustaining traumatic brain injury.” - Nguyen BM, Kim D, Bricker S, Bongard F, Neville A, Putnam B, Smith J, Plurad D. (2014)
  • “Various cannabinoids rescue dying neurones in experimental forms of acute neuronal injury, such as cerebral ischaemia and traumatic brain injury.” - Grundy RI (2002)
  • “A synthetic substance similar to ones found in marijuana stimulates cell growth in regions of the brain.” - University of Saskatchewan (2005)

Below are examples of studies that have found that cannabis is associated with effective pain management:

Below are examples of how cannabis is associated with a reduction of the use of harmful opioids:

  • “Many pain patients substituted prescription medications with cannabis (41.2-59.5%), most commonly opiates/opioids (40.5-72.8%).” - Baron, Lucas, Eades, Hogue (2018)
  • “Medical cannabis laws produce a statistically significant decrease in opioid prescription rates.” - Biles (2018)
  • “The treatment of chronic pain with medicinal cannabis in this open-label, prospective cohort resulted in improved pain and functional outcomes, and a significant reduction in opioid use.” - Haroutounian S, Ratz Y, Ginosar Y, Furmanov K, Saifi F, Meidan R, Davidson E. (2016)
  • “Cannabis use may decrease the use of other prescription medicines, including opioids.” - Abuhasira, Schleider, Mechoulam, Novack (2018)
  • “By the end of the 21 month observation period, MCP enrollment was associated with 17.27 higher age- and gender-adjusted odds of ceasing opioid prescriptions (CI 1.89 to 157.36, p = 0.012), 5.12 higher odds of reducing daily prescription opioid dosages (CI 1.56 to 16.88, p = 0.007), and a 47 percentage point reduction in daily opioid dosages relative to a mean change of positive 10.4 percentage points in the comparison group (CI -90.68 to -3.59, p = 0.034). The monthly trend in opioid prescriptions over time was negative among MCP patients (-0.64mg IV morphine, CI -1.10 to -0.18, p = 0.008), but not statistically different from zero in the comparison group (0.18mg IV morphine, CI -0.02 to 0.39, p = 0.081). Survey responses indicated improvements in pain reduction, quality of life, social life, activity levels, and concentration, and few side effects from using cannabis one year after enrollment in the MCP (ps<0.001).” - Vigil, Stith, Adams, Reeve (2017)
  • “Among respondents that regularly used opioids, over three-quarters (76.7%) indicated that they reduced their use since they started medical cannabis.” - Piper BJ1,2,3, DeKeuster RM4,5, Beals ML6, Cobb CM4,7, Burchman CA8,9, Perkinson L10, Lynn ST10, Nichols SD11, Abess AT12 (2017)
  • “Among study participants, medical cannabis use was associated with a 64% decrease in opioid use (n = 118), decreased number and side effects of medications, and an improved quality of life (45%). This study suggests that many CP patients are essentially substituting medical cannabis for opioids and other medications for CP treatment, and finding the benefit and side effect profile of cannabis to be greater than these other classes of medications.” - Boehnke KF, Litinas E, Clauw DJ. (2016)
  • “Sixty seven percent of patients stopped using opioid medications after using medical cannabis. In addition, 29 percent of patients reported a decrease in the number of opioid medications after starting medical cannabis.” - Aclara Research (2017)
  • “All prescriptions for scheduled medications must be reported to the New Mexico Prescription Monitoring Program with opiates and benzodiazepines being the two most common. Based on these prescription records, patients enrolled in the medical cannabis program reduced the monthly average number of prescriptions, types of prescriptions (drug classes), number of prescribers, and number of related pharmacy visits. 71% of medical cannabis program enrollees either ceased or reduced their use of scheduled prescriptions within 6 months of enrolling.” - Stith, S. S., et al (2017)
  • “The growing body of research supporting the medical use of cannabis as an adjunct or substitute for opioids creates an evidence-based rationale for governments, health care providers, and academic researchers to consider the implementation and assessment of cannabis-based interventions in the opioid crisis.” - Philippe Lucas (2017)
  • “The majority of patients in this study believed that medical marijuana is a valid treatment and that it does have a role in reducing post-injury and post-operative pain. Those patients who used marijuana during their recovery felt that it alleviated symptoms of pain and reduced their opioid intake.” - Heng, Marilyn MD, MPH, FRCSC; McTague, Michael F. MPH; Lucas, Robert C.

The studies listed above are just the tip of the iceberg. Cannabis use is not harmful to society – cannabis prohibition is harmful to society. The successful ACT reform measure will help law enforcement focus on fighting real crime. The territory will also save a considerable amount of public revenue from not having to enforce such a harmful, failed public policy.

Health Minister Greg Hunt is asking what was taken into consideration by ACT lawmakers prior to passing the legalization measure? The concerns that are being raised by Minister Hunt never became a reality in the growing list of jurisdictions that have legalized cannabis in various parts of the world, which begs the question – what exactly did Minister Hunt consider prior to starting his reefer madness campaign directed at the sensible law passed in the ACT? Was it science and logic, or was it outdated, harmful political opinions?

Which State Will Be The First To Legally Import/Export Cannabis In The U.S.?

Importing and exporting cannabis illegally between states is not a new thing in the U.S. Far from it. Ever since cannabis was federally prohibited in the 1930’s illegal cannabis sales have occurred in the U.S. with much of the cannabis involved having crossed one or more state borders along the way before making it to the end consumer.

Oregon lawmakers made history this year when they passed the first-ever cannabis import/export bill (not including hemp). The Craft Cannabis Alliance was instrumental in getting the bill passed and educating Oregon lawmakers on the benefits of cannabis import/export reform. The organization’s Founder and Director, Adam J. Smith, recently published an in-depth article about why other states need to be allowed to adopt measures similar to what Oregon’s Legislature passed in 2019. The article is a must-read.

The cannabis oversupply situation in Oregon was covered by mainstream media outlets numerous times in recent years. A lot of the media hysteria and hype is unwarranted considering that a significant amount of the oversupply is no longer usable and is simply lingering in Oregon’s seed-to-sale tracking system. However, that’s not to say that the recently passed reform measure was not needed.

Cannabis is an agriculture crop. it will likely always be regulated differently than tomatoes, but it’s ultimately a crop. Virtually all legal crops are imported and exported in some fashion between states. Demand for cannabis is very strong nationwide, so it is only logical to expect that at some point there will be a regulated system to help supply meet demand via interstate cannabis commerce.

A handful of states are exploring the idea of following in Oregon’s footsteps. Many cannabis observers are asking each other ‘when will the first legal cannabis import/export actually happen? When it does happen, which states will be involved?’

I have stated previously that I expect Oregon and Nevada to be the first states involved, with Oregon exporting sungrown cannabis to Nevada. That is still my prediction. For starters, Oregon is ready to enter into an interstate agreement right now, pending federal permission from the U.S. Department of Justice or via an act of Congress.

Nevada shares a border with Oregon and has allowed legal adult-use cannabis sales for awhile. Some cannabis observers have pointed out, and understandably so, that Nevada’s industry cultivates its own cannabis and so, therefore, its industry (and policymakers) would likely oppose allowing imports, and adamantly at that.

It’s a very valid point, however, it doesn’t take one important factor into account. Cannabis consumers want to make purchases, and if there is no supply at regulated outlets to make a purchase due to a shortage, they will turn to other sources, including the unregulated market which still exists and likely always will exist in Nevada.

Even if a consumer doesn’t turn to the unregulated market, they would immediately go to a competitor to purchase cannabis if their preferred outlet is out of stock or charging higher prices due to a shortage. As a desert state, Nevada’s climate is not ideal for cultivating quality cannabis under the sun, and that could be problematic over time.

A series of setbacks among large cultivators in Nevada could easily result in a situation where cannabis is in short supply, similar to what is currently going on in parts of Colorado, or occurred in California after large wildfires destroyed huge cannabis farms. The demand for cannabis in the state of Nevada will remain constant if/when a shortage happens. What will the state do to help fill the void?

Entrepreneurs, regulators, and even lawmakers have a vested interest in keeping Nevada’s legal cannabis industry humming along in order to keep consumers from turning to the unregulated market. Importing cannabis legally from another state is a logical solution to the problem if/when it happens, and Oregon is the perfect partner to help fill the void if that ever proves to be the case in Nevada.

A policy allowing Nevada to import legal cannabis from Oregon would not necessarily be designed to replace Nevada’s cannabis cultivation sector. Rather, it would be geared towards helping supplement it. In some instances, it may make more financial sense to import cannabis from Oregon to the Nevada market. After all, Oregon’s cultivation community is capable of producing a tremendous amount of world-class cannabis at likely a cheaper price than any other state.

However, many consumers would still likely prefer to buy locally-sourced cannabis. After the local sources run out, entrepreneurs would then turn to Oregon to help fill the void to keep the supply steady. Eventually, most states will have cannabis from a laundry list of other states on regulated shelves in their jurisdictions, just as they do a number of other consumables (including alcohol). Yet, before that happens, two states will have to be the first to put things in motion.

That could happen even prior to federal permission being granted. After all, it wouldn’t be the first time that Oregon and Nevada defied federal cannabis law. It’s not likely, but it’s certainly not a far-fetched concept either.

One wild-card scenario is worth touching on in this discussion. A way that I can see cannabis imports/exports occurring in a scenario that doesn’t involve Oregon or Nevada could possibly be via a social-equity multi-state program. This type of public policy concept would involve social-equity cultivation licensees in one state exporting their cannabis to social-equity licensees in another state.

When a state initially passes a reform measure creating a legal cannabis industry, it takes quite a bit of time for cannabis companies to go from obtaining a license and starting a cannabis cultivation facility all the way to actually selling products to the end consumer. In states with no regulatory framework in place, that process could take years.

With enormous startup costs and the length of time involved until a sale is made in the scenario described, many would-be cannabis entrepreneurs simply wouldn’t have the resources to get involved in the cannabis industry in a meaningful way. That is especially true for members of communities disproportionately affected by cannabis prohibition.

State-to-state equity programs would not only help mitigate the issues described, but it would also give social-equity licensees a significant headstart over people and entities with huge resources, which is something that the cannabis industry, regulators, and lawmakers everywhere should all be embracing. I would personally love to see it happen.

For the time being though, it seems like other states are unlikely to beat Oregon and Nevada to the punch. If that did happen, it would take a perfect storm. Nevada is home to a huge demand for cannabis in a desert climate, and Oregon has the ability to cultivate world-class cannabis on the other side of the state border. Oregon also already has a policy in place (albeit without the regulations). That scenario does not exist anywhere else in the United States right now.

California is another likely candidate to help fill any potential supply voids in Nevada. After all, California can also cultivate world-class cannabis and also shares a border with Nevada. However, Oregon is much farther along on the policy side, and California is still working on addressing its own intrastate commerce hurdles and issues, so I think a California-to-Nevada scenario is far less likely to occur than an Oregon-to-Nevada scenario.

Former Health Canada Inspector Dr. Sherry Boodram Joins Nextleaf Solutions Board Of Directors

Nextleaf Solutions, a leading cannabis extraction technology company, has announced today that it has added Dr. Sherry Boodram, former Senior Regulatory Compliance Officer with Health Canada, to its Board of Directors, effective immediately.

Dr. Sherry Boodram worked for the Canadian federal government for several years and was responsible for licensing application reviews and on-site facility inspections of Canadian cannabis industry facilities.

Dr. Boodram also provided field level input during the drafting of the current Canadian cannabis regulations.

“Being a company with values I can stand behind, I’m very excited to serve alongside Nextleaf’s existing Board members and with their talented executive team,” stated Dr. Sherry Boodram. “Moreover, I look forward to maximizing the unique knowledge and experience I gained while at Health Canada’s Medical Cannabis Program, and in the cannabis industry as a whole, to provide expertise in support of Nextleaf’s ongoing commitment to regulatory compliance, good governance, and long-term growth as a leader in cannabis extraction technology.”

Dr. Boodram holds a Ph.D. in Chemistry from York University, a B.Sc. (Hon) from the University of Toronto, and a Graduate Certificate with Honours in Pharmaceutical Regulatory Affairs and Quality Operations from Seneca College. Dr. Boodram is also a member of the Canadian Association of Professionals in Regulatory Affairs (CAPRA).

Currently, Dr. Boodram is the co-founder and CEO of CannDelta Inc. (“CannDelta”) – a regulatory and scientific cannabis consulting company based out of Toronto, Canada – where she provides regulatory expertise and develops strategies to ensure regulatory compliance within Canada’s existing legal cannabis framework.

“The serious regulatory infractions by several large Canadian licensed cannabis producers, along with an expanded scope of cannabis products through legalization 2.0, reinforces the critical role that compliance oversight plays in building a cannabis company all stakeholders can be proud of,” stated Paul Pedersen, co-founder and CEO of Nextleaf Solutions. “Sherry is amongst the most credible and qualified cannabis regulatory experts in Canada, and we believe her background, insights, and industry experience will add tremendous value to our Board.”

About Nextleaf Solutions

Nextleaf Solutions Ltd. (“OILS”) is developing disruptive intellectual property for industrial-scale extraction, purification, and formulation of cannabinoids. OILS owns a portfolio of eight (8) issued and 35 pending patents pertaining to the production of high-purity, cannabinoid-rich distillate, the key ingredient used in the manufacturing of standardized THC and CBD infused products. Once cannabis concentrates and edibles become legal across Canada, OILS plans to commercialize its intellectual property portfolio through IP licensing, B2B processing services, and the supply of THC and CBD oils and concentrates to qualified Canadian and international partners.

Nextleaf Solutions trades as OILS on the Canadian Securities Exchange (CSE: OILS), OILFF on the OTCQB Market in the United States (OTCQB: OILFF) and L0MA on the Frankfurt Stock Exchange (FSE: L0MA).

For more information visit www.nextleafsolutions.com or follow OILS across social media platforms: Twitter, LinkedIn, Facebook, and Instagram.